Oculis Holding AG
corporate_fare Company Profile
Oculis Holding AG (NASDAQ:OCS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for OCS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for OCS spans 6-K, F-3ASR, 20-F.
Recent high-impact activity:
- FDA Clears IND, Opening Acute MS Relapse Path for Privosegtor
- Oculis Q3 Loss Widens to CHF 18.2M as Expenses Climb; Cash Runs Into 2H 2029
- Oculis Upsizes ATM to $125M and Posts Narrower Q3 Loss With Runway Into 2H 2029
- Oculis Secures Full Worldwide Rights to Privosegtor, Eliminating Legacy Royalties
- Oculis Buys Out Privosegtor Rights from Accure for $3.8M Cash and 2M Shares, Ending Royalty Obligations
Financial Snapshot
Short Interest & Short Volume
5.64 days to coverFINRA reported short interest of 1,583,743 shares in OCS as of the October 30, 2026 settlement, a 11.3% decrease from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 52.2% of OCS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OCS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-03.
ATM Capacity Raised to $125 Million · $61.3 Million Already Sold Under Prior ATM
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
OCS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.